877-202-0205     support@chemchart.com     @chemchart
        
Sign In    Register
   Reset Filters

Cardiovascular system drug, Spiro compounds

Categories

Antiandrogens (5)
Antihypertensive agents (5)
Antimineralocorticoids (5)
Diuretics (5)
Drugs acting on the cardiovascular system (5)
Drugs acting on the genito-urinary system (5)
Hormonal agents (5)
Potassium-sparing diuretics (5)
Sex hormones (5)
Systemic hormonal preparations (5)
Cyclic compounds (3)
Cycloalkanes (3)
Cyclopropanes (3)
Progestogens (3)
Three-membered rings (3)

Prorenone (49848-04-6)  
Prorenone (developmental code name SC-23133) is a steroidal antimineralocorticoid of the spirolactone group related to spironolactone that was never marketed. It is the lactonic form of prorenoic acid (prorenoate), and prorenoate potassium (SC-23992), the potassium salt of prorenoic acid, also exists. Prorenoate potassium is about 8 times more potent than spironolactone as an antimineralocorticoid in animals, and it may act as a prodrug to prorenone.
Spirorenone (74220-07-8)  
6 beta, 7 beta, 15 beta, 16 beta-dimethylene-1,4-androstadiene-(17(beta-1')-spiro-5')-perhydrofuran-2',3-dione
Spirorenone (INN) (developmental code name ZK-35973) is a steroidal antimineralocorticoid of the spirolactone group that was never marketed. Spirorenone possesses 5–8 times the antimineralocorticoid activity of spironolactone in animal studies. The initial discovery of spirorenone was deemed a great success, as no compound with greater antimineralocorticoid activity had been developed since spironolactone in 1957.
20-Spirox-4-ene-3,20-dione (976-70-5)  
SC-5233, also known as 6,7-dihydrocanrenone or 20-spirox-4-ene-3,20-dione, is a steroidal antimineralocorticoid of the spirolactone group which was developed by G. D. Searle & Company in the 1950s but was never marketed.
Related searches
Cardiovascular system drug
Spiro compounds